-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Comera Life Sciences Holdings, Inc. (NASDAQ:CMRAW) Short Interest Update
Comera Life Sciences Holdings, Inc. (NASDAQ:CMRAW) Short Interest Update
Comera Life Sciences Holdings, Inc. (NASDAQ:CMRAW – Get Rating) was the recipient of a large drop in short interest in November. As of November 30th, there was short interest totalling 15,000 shares, a drop of 14.3% from the November 15th total of 17,500 shares. Based on an average daily volume of 51,100 shares, the days-to-cover ratio is currently 0.3 days.
Institutional Investors Weigh In On Comera Life Sciences
A hedge fund recently bought a new stake in Comera Life Sciences stock. Warberg Asset Management LLC bought a new position in Comera Life Sciences Holdings, Inc. (NASDAQ:CMRAW – Get Rating) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 202,000 shares of the company's stock, valued at approximately $29,000.
Get Comera Life Sciences alerts:Comera Life Sciences Stock Performance
NASDAQ CMRAW remained flat at $0.06 during mid-day trading on Friday. The company's stock had a trading volume of 3 shares, compared to its average volume of 165,797. Comera Life Sciences has a 12-month low of $0.03 and a 12-month high of $0.70. The firm's fifty day moving average price is $0.06.
About Comera Life Sciences
(Get Rating)Comera Life Sciences Holdings, Inc, a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform, SQore. Its SQore platform is designed to enable the conversion of intravenous (IV) biologics to subcutaneous (SQ) versions.
See Also
- Get a free copy of the StockNews.com research report on Comera Life Sciences (CMRAW)
- MarketBeat: Week in Review 12/12 – 12/16
- Which Two Bluechip Tech Companies Have Raised Their Guidance?
- Should You Worry About Elon Musk Selling His Tesla Shares?
- Can Tractor Supply Stock Surge Past Cup-With-Handle Buy Point?
- This is no Time to Buy Lennar but the Time is Coming
Receive News & Ratings for Comera Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Comera Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
Comera Life Sciences Holdings, Inc. (NASDAQ:CMRAW – Get Rating) was the recipient of a large drop in short interest in November. As of November 30th, there was short interest totalling 15,000 shares, a drop of 14.3% from the November 15th total of 17,500 shares. Based on an average daily volume of 51,100 shares, the days-to-cover ratio is currently 0.3 days.
科美拉生命科学控股公司(纳斯达克代码:CMRAW-GET Rating)是空头股数11月份股价大幅下跌的接受者。截至11月30日,空头股数共有15,000股,较11月15日的17,500股下降了14.3%。以日均成交量51,100股计算,目前天数与回补比率为0.3天。
Institutional Investors Weigh In On Comera Life Sciences
机构投资者看好科美拉生命科学
A hedge fund recently bought a new stake in Comera Life Sciences stock. Warberg Asset Management LLC bought a new position in Comera Life Sciences Holdings, Inc. (NASDAQ:CMRAW – Get Rating) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 202,000 shares of the company's stock, valued at approximately $29,000.
一家对冲基金最近购买了科美拉生命科学公司的新股。根据华伯格资产管理公司在最近提交给美国证券交易委员会的文件中,该公司在第二季度购买了科梅拉生命科学控股公司(纳斯达克:CMRAW-GET Rating)的一个新头寸。该公司购买了20.2万股该公司股票,价值约2.9万美元。
Comera Life Sciences Stock Performance
科美拉生命科学类股表现
NASDAQ CMRAW remained flat at $0.06 during mid-day trading on Friday. The company's stock had a trading volume of 3 shares, compared to its average volume of 165,797. Comera Life Sciences has a 12-month low of $0.03 and a 12-month high of $0.70. The firm's fifty day moving average price is $0.06.
在周五午盘交易中,纳斯达克CMRAW持平于0.06美元。该公司股票的交易量为3股,而其平均成交量为165,797股。Comera Life Sciences的股价为0.03美元,为12个月低点,12个月高位为0.70美元。该公司的50日移动均线价格为0.06美元。
About Comera Life Sciences
科美拉生命科学公司简介
Comera Life Sciences Holdings, Inc, a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform, SQore. Its SQore platform is designed to enable the conversion of intravenous (IV) biologics to subcutaneous (SQ) versions.
Comera生命科学控股公司是一家临床前阶段的生命科学公司,该公司开发了一个内部专有疗法组合,其中纳入了其专有配方平台Sqore。其Sqore平台旨在实现静脉(IV)生物制品到皮下(SQ)制剂的转换。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Comera Life Sciences (CMRAW)
- MarketBeat: Week in Review 12/12 – 12/16
- Which Two Bluechip Tech Companies Have Raised Their Guidance?
- Should You Worry About Elon Musk Selling His Tesla Shares?
- Can Tractor Supply Stock Surge Past Cup-With-Handle Buy Point?
- This is no Time to Buy Lennar but the Time is Coming
- 免费获取StockNews.com关于Comera生命科学的研究报告(CMRAW)
- MarketBeat:回顾一周12/12-12/16
- 哪两家蓝筹科技公司提高了他们的指引?
- 你应该担心埃隆·马斯克出售他持有的特斯拉股票吗?
- 拖拉机库存能否突破杯柄收购点?
- 现在不是购买Lennar的时候,但时机即将到来
Receive News & Ratings for Comera Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Comera Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受Comera生命科学日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Comera生命科学和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧